An interventional study of Blood samples will be collected at different times. in Leiomyosarcoma, sponsored by Institut Claudius Regaud. Active, not recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-03.
Sponsored by Institut Claudius Regaud · Not applicable, Interventional, and Other
Pilot, prospective, monocentric study aimed at evaluating the rate of patients with circulating "cancer cell/macrophage" hybrid cells in the peripheral blood and the evolution of this rate over time.
The study will be conducted on a population of patients with leiomyosarcoma and treated in the context of routine care. 20 patients will be included:
For each included patient, blood samples will be collected during baseline visit and up to 24 months after inclusion.
147 studies on the registry are indexed under Leiomyosarcoma; 33 are open to participants now.
This study's planned enrollment of 20 is below the median of 45 across 121 interventional studies indexed under Leiomyosarcoma.
Browse Leiomyosarcoma studies →Institut Claudius Regaud is the lead sponsor of 117 studies on the registry; 34 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Other: Blood samples will be collected at different times.
For patients with localized leiomyosarcoma, samples will be collected: * At Baseline. * Before surgery (for patients who have had neoadjuvant treatment (external radiotherapy and/or chemotherapy)). * After surgery. * At each control visit. * At local or metastatic recurrence (or at 24 months post inclusion if no progression). For patients with metastatic leiomyosarcoma, samples will be collected: * At Baseline. * At each therapeutic line. * At progression (or at 24 months post inclusion if no progression).
The longitudinal evolution of rate of patients with "cancer cell / macrophage" hybrid cells in peripheral blood.
Time frame: 24 months after the end of inclusions.
Quantification of circulating hybrid cells in peripheral blood by automatic measurement (Cell Counter Corning) and expressed in number of cells / millilitre of blood.
Time frame: 24 months after the end of inclusions.
This study is active, not recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut Claudius Regaud